KD 018

Drug Profile

KD 018

Alternative Names: KD018; PHY-906

Latest Information Update: 11 May 2015

Price : $50

At a glance

  • Originator PhytoCeutica
  • Developer Kadmon Corporation; PhytoCeutica
  • Class Chemoprotectants
  • Mechanism of Action Acetylcholinesterase modulators; Acetyltransferase modulators; Cytochrome P 450 enzyme system inhibitors; Metalloprotease inhibitors; NF-kappa B inhibitors; Opioid delta receptor antagonists; P-glycoprotein inhibitors; Tachykinin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Gastrointestinal disorders; Hepatocellular carcinoma; Pancreatic cancer

Most Recent Events

  • 11 May 2015 Discontinued - Phase-I/II for Gastrointestinal disorders (Chemotherapy-induced) in USA (PO)
  • 11 May 2015 Discontinued - Phase-I/II for Hepatocellular carcinoma (Adjunctive treatment, Combination therapy) in USA (PO)
  • 11 May 2015 Discontinued - Phase-I/II for Colorectal cancer (Adjunctive treatment, Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top